187 related articles for article (PubMed ID: 20150180)
1. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties.
Wozniak-Knopp G; Bartl S; Bauer A; Mostageer M; Woisetschläger M; Antes B; Ettl K; Kainer M; Weberhofer G; Wiederkum S; Himmler G; Mudde GC; Rüker F
Protein Eng Des Sel; 2010 Apr; 23(4):289-97. PubMed ID: 20150180
[TBL] [Abstract][Full Text] [Related]
2. In vivo and in vitro activity of an immunoglobulin Fc fragment (Fcab) with engineered Her-2/neu binding sites.
Woisetschläger M; Antes B; Borrowdale R; Wiederkum S; Kainer M; Steinkellner H; Wozniak-Knopp G; Moulder K; Rüker F; Mudde GC
Biotechnol J; 2014 Jun; 9(6):844-51. PubMed ID: 24806546
[TBL] [Abstract][Full Text] [Related]
3. Directed evolution of Her2/neu-binding IgG1-Fc for improved stability and resistance to aggregation by using yeast surface display.
Traxlmayr MW; Lobner E; Antes B; Kainer M; Wiederkum S; Hasenhindl C; Stadlmayr G; Rüker F; Woisetschläger M; Moulder K; Obinger C
Protein Eng Des Sel; 2013 Apr; 26(4):255-65. PubMed ID: 23267121
[TBL] [Abstract][Full Text] [Related]
4. Correlation between CD16a binding and immuno effector functionality of an antigen specific immunoglobulin Fc fragment (Fcab).
Kainer M; Antes B; Wiederkum S; Wozniak-Knopp G; Bauer A; Rüker F; Woisetschläger M
Arch Biochem Biophys; 2012 Oct; 526(2):154-8. PubMed ID: 22634259
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
[TBL] [Abstract][Full Text] [Related]
6. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
7. Fcab-HER2 Interaction: a Ménage à Trois. Lessons from X-Ray and Solution Studies.
Lobner E; Humm AS; Göritzer K; Mlynek G; Puchinger MG; Hasenhindl C; Rüker F; Traxlmayr MW; Djinović-Carugo K; Obinger C
Structure; 2017 Jun; 25(6):878-889.e5. PubMed ID: 28528777
[TBL] [Abstract][Full Text] [Related]
8. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
9. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
10. Designing Fcabs: well-expressed and stable high affinity antigen-binding Fc fragments.
Wozniak-Knopp G; Stadlmayr G; Perthold JW; Stadlbauer K; Woisetschläger M; Sun H; Rüker F
Protein Eng Des Sel; 2017 Sep; 30(9):657-671. PubMed ID: 28981753
[TBL] [Abstract][Full Text] [Related]
11. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
12. Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells.
Somasundaram C; Sundarapandiyan K; Keler T; Deo YM; Graziano RF
Hum Antibodies; 1999; 9(1):47-54. PubMed ID: 10331185
[TBL] [Abstract][Full Text] [Related]
13. Refined structure of an intact IgG2a monoclonal antibody.
Harris LJ; Larson SB; Hasel KW; McPherson A
Biochemistry; 1997 Feb; 36(7):1581-97. PubMed ID: 9048542
[TBL] [Abstract][Full Text] [Related]
14. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.
Davis JH; Aperlo C; Li Y; Kurosawa E; Lan Y; Lo KM; Huston JS
Protein Eng Des Sel; 2010 Apr; 23(4):195-202. PubMed ID: 20299542
[TBL] [Abstract][Full Text] [Related]
15. Construction of pH-sensitive Her2-binding IgG1-Fc by directed evolution.
Traxlmayr MW; Lobner E; Hasenhindl C; Stadlmayr G; Oostenbrink C; Rüker F; Obinger C
Biotechnol J; 2014 Aug; 9(8):1013-22. PubMed ID: 24964247
[TBL] [Abstract][Full Text] [Related]
16. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
17. Engineered IgG1-Fc--one fragment to bind them all.
Lobner E; Traxlmayr MW; Obinger C; Hasenhindl C
Immunol Rev; 2016 Mar; 270(1):113-31. PubMed ID: 26864108
[TBL] [Abstract][Full Text] [Related]
18. Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185(c-erbB-2).
Cheng LS; Liu AP; Yang JH; Dong YQ; Li LW; Wang J; Wang CC; Liu J
Cell Res; 2003 Feb; 13(1):35-48. PubMed ID: 12643348
[TBL] [Abstract][Full Text] [Related]
19. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.
Chen Y; Wiesmann C; Fuh G; Li B; Christinger HW; McKay P; de Vos AM; Lowman HB
J Mol Biol; 1999 Nov; 293(4):865-81. PubMed ID: 10543973
[TBL] [Abstract][Full Text] [Related]
20. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
